Orbitrap Fusion Lumos Tribrid Mass Spectrometer wins Scientists’ Choice Award for Best New Drug Discovery Product of 2015
This award recognizes the company with the highest reviews and ratings on SelectScience.
The global community of SelectScience readers and contributors has named the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer the Best New Drug Discovery Product of 2015. This award recognizes the company with the highest reviews and ratings on SelectScience, an online resource that fulfills the information needs of the global scientific community.
SelectScience announced the winner this week at an awards ceremony at the Annual Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS) in San Diego. Last year, the SelectScience community awarded the Thermo Scientific Vanquish High-Performance Liquid Chromatography system with Best New Separations Product and named Thermo Fisher Scientific as Company of the Year.
“This Scientists’ Choice Award celebrates the new technologies that made the biggest impact in drug discovery and development research in 2015,” said Arif Butt, CEO and founder of SelectScience. “The awards are unique in this industry as they empower scientists to nominate and vote for their favorite new product, enabling them to have their say in the manufacturers that have truly enabled their work. Congratulations to Thermo Fisher Scientific on this significant achievement.”
“We aim to deliver technology innovations that enable our customers to make impactful scientific discoveries,” said Dan Shine, senior vice president, analytical instruments at Thermo Fisher. “Ten years ago, we introduced the first Orbitrap-based mass spectrometer and this opened up new possibilities in life sciences research. Since then, we have continued to deliver new levels of performance for scientists conducting the most challenging work. We are proud that the scientific community recognizes the pioneering contributions of our newest addition, the Orbitrap Fusion Lumos MS.”
Scientists pushing the limits of quantitation and protein characterization require more expansive and in-depth analytical information. The Orbitrap Fusion Lumos Tribrid MS addresses this need for scientists conducting proteomics, biopharma and metabolomics research. The broad advances made in the new-generation Orbitrap Fusion Lumos MS instrument deliver increased sensitivity and an enhanced feature set, allowing scientists to perform more comprehensive sample analyses faster and with better accuracy than our mass spectrometers ever have before.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.